ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Total Debt
Short-term and long-term borrowings combined.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 203.6% from a year ago
Total debt stood at $419K at the end of Q1 FY2026, up 203.6% from a year earlier and up 2892.9% from the prior quarter. Over 3 fiscal years it compounded at -53.5% a year.
Context
- Total debt amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +203.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 14K USD
- Year-over-year change
- -92.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14K | -92.0% |
| FY2024 | 2024-12-31 | 176K | -44.5% |
| FY2023 | 2023-12-31 | 317K | +128.1% |
| FY2022 | 2022-12-31 | 139K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's Mar 2026 total debt of $419K is the lowest of the 11 companies compared; the peer median is $36M.
- Its year-over-year change of +203.6% is the 2nd highest of 11, against a peer median of -2.2%.
- Total debt amounts to 0.1% of total assets for AVBP, versus a peer median of 6.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $254.58M | +33.0% | +122.4% | 23.7% | |
| Jun 2026 | $252.14M | +336.5% | +33.5% | 33.9% | |
| Jul 2026 | $165.93M | -7.7% | -3.1% | 6.7% | |
| Dec 2025 | $97.89M | +9.0% | +53.6% | 5.6% | |
| Sep 2026 | $43.41M | -10.1% | -5.1% | 4.3% | |
| Mar 2026 | $28.6M | +10.1% | +100.1% | 2.8% | |
| Mar 2026 | $17.88M | -17.2% | -12.6% | 13.5% | |
| Mar 2026 | $15.95M | -74.1% | -37.0% | 8.3% | |
| Mar 2026 | $5.7M | -6.9% | +30.4% | 1.4% | |
| Mar 2026 | $3.3M | +2.6% | -1.5% | 0.8% | |
| Mar 2026 | $419K | +203.6% | -53.5% | 0.1% | |
| Peer median (excluding AVBP) | $36M | -2.2% | +14.4% | 6.1% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37.28M | 163.37M | 150.39M | 74.29M | 45.54M |
| Short-term Investments | 0 | 0 | 0 | 144.57M | 267.28M |
| Net Receivables | 0 | 0 | 0 | 500K | 60K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.64M | 18.92M | 9.21M | 7.21M | 20.02M |
| Total Current Assets | 42.95M | 182.62M | 159.97M | 226.98M | 332.9M |
| Property, Plant & Equipment (Net) | 0 | 139K | 291K | 154K | 13K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 47.68M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87K | 72K | 2.84M | 126K | 259K |
| Total Non-current Assets | 87K | 211K | 3.13M | 47.96M | 272K |
| Total Assets | 43.04M | 182.83M | 163.1M | 274.94M | 333.17M |
| Account Payables | 293K | 3.09M | 4.53M | 3.78M | 5.93M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 4.16M | 6.55M |
| Total Current Liabilities | 1.82M | 8.36M | 11.62M | 17.27M | 25.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 11K | 177K | 14K | 0 |
| Total Liabilities | 1.82M | 8.37M | 11.8M | 17.29M | 25.95M |
| Common Stock | 0 | 0 | 0 | 3K | 4K |
| Retained Earnings | (51.61M) | (88.51M) | (157.85M) | (238.33M) | (404.64M) |
| Accumulated OCI | (2K) | 0 | 0 | (211K) | 14K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.22M | 174.46M | 151.3M | 257.65M | 307.22M |
| Total Debt | 0 | 139K | 317K | 176K | 14K |
| Net Debt | (37.28M) | (163.23M) | (150.07M) | (74.12M) | (45.53M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.